According to the Russian Registry of Clinical Trials, OCT Clinical is among the top 3 CROs by the number of clinical trials launched in 2020. The OCT team managed to secure approvals from the Russian Ministry of Health for 10 new clinical research projects. Among other local companies who made it into the top-5 are iPharma, ClinPharmInvest, Probiotech and ClinPharmDevelopment. In addition, OCT Clinical entered the list of the top 10 global and local CROs along with Iqvia (32), Parexel (19), PPD (14) and Syneos Health (12).
In 2020 OCT Clinical initiated projects for various pharmaceutical companies from Asia (Handok Inc.), and Europe (Stayble Therapeutics), and for several solid US biotech companies. Indeed, OCT Clinical was called upon by CanSino Biologics Inc. in 2020 to be the principal contract research organization in Russia that conducted one of the largest international studies for COVID-19 vaccine with 8,000 volunteers.
"2020 was a challenging year for the whole industry," commented Dmitry Sharov, the CEO of OCT Clinical. “Nevertheless, thanks to close cooperation with research sites, swift optimization and partial automation of processes, we managed not only to keep working on clinical trials, but also to continue working in compliance with all standards and quality guidelines ensuring safety for all research participants."
Most of trials launched by OCT Clinical in 2020 included those in oncology, infectious diseases, neurology and rheumatology. In total, the CRO has more than 300 clinical research projects in 29 therapeutic areas in its portfolio.